Existing Investors Participate Again… Strengthening Products and Business Strategy, Accelerating Global Expansion

AITRICS (CEO Kwang Joon Kim), a company specializing in artificial intelligence(AI) technology announced on December 1 that it has successfully raised KRW 35 billion in Series C funding from nine domestic and international venture capital and financial institutions.

Existing investors, including Premier Partners, Hanriver Partners, Mirae Asset Venture Investment, and ShinYoung Securities-BSK Investment, participated in this round. New investors joining the round include KB Securities-Solidus Investment, SV Investment, and Mirae Asset Capital.

Through this funding, AITRICS has been recognized for its differentiated technology, proven clinical efficacy, and potential for global expansion. The capital will be allocated to enhance the capabilities of its flagship products— the inpatient deterioration prediction solution AITRICS-VC (VitalCare) and the clinician copilot AI solution V.Doc Pro—as well as to support research and development (R&D) for new pipelines and other core strategic initiatives.

AITRICS is also expanding its international presence. The company established a local subsidiary in Japan in March to lay the groundwork for operations, with plans to expand further into Asia, including Vietnam and Hong Kong. In addition, AITRICS set up a U.S. subsidiary in December 2023 to pave the way for entry into the North American market. Through recent collaboration with the Mayo Clinic Platform, the company is advancing model validation and defining strategies for global expansion.

CEO Kwang Joon Kim stated, “We are grateful for the continued trust and support from our investors, which reaffirmed our company’s direction and growth potential. The repeated participation of the same institutions shows that our business strategy and products are consistently recognized. The secured funds will enable us to implement our mid- to long-term strategy stably and significantly strengthen the company’s growth and competitiveness.”

An SV Investment representative commented, “We decided to invest in AITRICS after confirming its innovative AI solutions, excellent clinical performance, and clear business strategy. We expect this investment to accelerate indication expansion and global market entry. Based on this, AITRICS is poised to become an essential AI solutions provider in the global healthcare field.”

Since its founding, AITRICS has raised a total of KRW 75 billion in seed investment (2017) and Series A (2019), KRW 3.5 billion in Pre-Series B (2021), and KRW 27.1 billion in Series B (2024). With the inclusion of the Series C round, the company has secured a cumulative total of KRW 73.1 billion in funding.